Functional macrophages and gastrointestinal disorders

Yue-Hong Liu, Yue Ding, Chen-Chen Gao, Li-Sheng Li, Yue-Xiu Wang, Jing-Dong Xu

Yue-Hong Liu, Yue Ding, School of Basic Medical Science, Beijing Capital Medical University, Beijing 100069, China

Chen-Chen Gao, Jing-Dong Xu, Department of Physiology and Pathophysiology, School of Basic Medical Science, Capital Medical University, Beijing 100069, China

Li-Sheng Li, Function Platform Center, School of Basic Medical Science, Capital Medical University, Beijing 100069, China

Yue-Xiu Wang, Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China

ORCID number: Yue-Hong Liu (0000-0002-6618-3511); Yue Ding (0000-0001-6291-6848); Chen-Chen Gao (0000-0002-3730-0272); Li-Sheng Li (0000-0002-7255-6863); Yue-Xiu Wang (0000-0002-3243-3092); Jing-Dong Xu (0000-0003-4546-563X).

Author contributions: Liu YH and Ding Y contributed equally to the writing of this manuscript; Liu YH, Ding Y and Xu JD wrote the manuscript; Liu YH and Gao CC designed the illustrations; Li LS and Wang YX analyzed the data; Xu JD revised the manuscript.

Supported by National Natural Science Foundation of China, No. 81274173, No. 81673671 and No. 81270443; Beijing National Science Foundation, No. 7122017.

Conflict-of-interest statement: The authors do not have any relevant conflicts of interest (including relevant financial interests, activities, relationships and/or affiliations).

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Correspondence to: Jing-Dong Xu, PhD, Assistant Professor, Department of Physiology and Pathophysiology, School of Basic Medical Science, Capital Medical University, No. 10, Xitoutiao, You An Menwai, Fengtai District, Beijing 100069, China. xujingdong@163.com

Received: January 27, 2018
Peer-review started: January 28, 2018
First decision: February 10, 2018
Revised: February 12, 2018
Accepted: February 25, 2018
Article in press: February 25, 2018
Published online: March 21, 2018

Abstract

Macrophages (MΦ) differentiate from blood monocytes and participate in innate and adaptive immunity. Because of their abilities to recognize pathogens and activate bactericidal activities, MΦ are always discovered at the site of immune defense. MΦ in the intestine are unique, such that in the healthy intestine, they possess complex mechanisms to protect the gut from inflammation. In these complex mechanisms, they produce anti-inflammatory cytokines, such as interleukin-10 and transforming growth factor-β, and inhibit the inflammatory pathways mediated by Toll-like receptors. It has been demonstrated that resident MΦ play a crucial role in maintaining intestinal homeostasis, and they can be recognized by their unique markers. Nonetheless, in the inflamed intestine, the function of MΦ will change because of environmental variation, which may be one of the mechanisms of inflammatory bowel disease (IBD). We provide further explanation about these mechanisms in our review. In addition, we review recent discoveries that MΦ may be involved in the development of gastrointestinal tumors. We will highlight the possible therapeutic targets for the management of IBD and gastrointestinal tumors, and we also discuss why more details are needed to fully
understand all other effects of intestinal MΦ.

Key words: Macrophages; Homeostasis; Inflammatory bowel disease; Gastrointestinal tumors; Therapeutic targets

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The manuscript involves three components. First, after briefly describing the origin of macrophages (MΦ), it summarizes their general biologic features and common functions. The second component reveals the differences between resident MΦ in the intestine and those in other tissues. Notably, we depicted how resident MΦ participate in maintaining intestinal homeostasis and why they can maintain intestinal health by comparison between each of these distinct features. The third part discusses how the deficiency of this anti-inflammatory system leads to autoimmune diseases. However, we also discuss the many details of why intestinal MΦ and the underlying mechanism of inflammatory bowel disease and gut tumors remain obscure.

Liu YH, Ding Y, Gao CC, Li LS, Wang YX, Xu JD. Functional macrophages and gastrointestinal disorders. World J Gastroenterol 2018; 24(11): 1181-1195 Available from: URL: http://www.wjgnet.com/1007-9327/full/v24/i11/1181.htm DOI: http://dx.doi.org/10.3748/wjg.v24.i11.1181

INTRODUCTION

The intestine is organized into distinct specialized and functional tissues, such as the epithelium and lamina propria (LP). As the major site of bacterial colonization (10^11 cfu/mL in the duodenum, 10^2 cfu/mL in the jejunum, 10^1 cfu/mL in the proximal ileum, 10^2-10^9 cfu/mL in the distal ileum, and 10^11-10^12 cfu/mL in the colon[1]), it is crucial to maintain intestinal homeostasis in which the intestinal immune system contributes to such maintenance under physiological conditions. Meanwhile, both commensal bacteria and their products play important roles[2].

The mammalian intestine is considered the largest immune organ in the body. It is estimated that 65%-80% of the immune cells, such as macrophages (MΦ), dendritic cells (DCs), T cells and B cells[3], exist in the intestine. There are many lymphocytes and natural killer (NK) cells in the region of the epithelial base[4,5]. Most of the intraepithelial lymphocytes are T cells, and they express CD3, CD8[6], TCRαβ[3] or TCRγδ[7] (mainly in mice). Goblet cells of the intestinal epithelium secrete net-like MUC2 mucins that compose the surface mucus layer, which can filter out microbes[8,9]. Both the intestinal epithelium and mucus layer constitute the double-protective barrier to maintain homeostasis at the entrance where pathogens invade. With the background described above, it seems that MΦ are insignificant in the intestinal immune system. In fact, they play a unique supporting role in maintaining the balance of intestinal immunity, and they are by no means as simple as we thought.

MΦ are one of the nonhematopoietic cells in all mammalian species that are distributed throughout the tissues of individuals. Their origin is relatively clear, and their biologic features have long been explored. In terms of immune defense, their name reveals their function: phagocytosis. They participate in innate immune responses and adaptive immune responses, especially in the intestine, which is the largest pool of MΦ and commensal bacteria. They can be considered as regulators instead of inflammation propellants (see below).

Emerging evidence suggests that intestinal resident MΦ contribute to maintaining intestinal homeostasis by several mechanisms (see below), and the production of immunosuppressive cytokines and their inhibitory biologic behavior suppress cascaded inflammatory responses. This is beneficial to the host because they protect the intestine from over-responding to commensal bacteria, resulting in severe tissue damage. Thus, they have attracted increasing attention in research on intestinal homeostasis and the correlative mechanisms of intestinal autoimmune diseases, represented by inflammatory bowel disease (IBD).

IBD includes two types of diseases: ulcerative colitis (UC) and Crohn’s disease (CD). IBD has long been considered a typical autoimmune disease. Several reports have confirmed that multiple factors, for example, epithelial defects, disturbance of commensal or pathogenic bacteria and destruction of the mucus layer, lead to the development of IBD. In addition, intestinal MΦ highlight the defects of their protective function in IBD.

In addition, we propose some promising targets for the studies and treatments of IBD and gastrointestinal tumors. These comprehensive descriptions and findings of MΦ above have been summarized in figures of our manuscript to make the unique function of intestinal MΦ more understandable.

MACROPHAGES: DIFFERENTIATION AND BIOLOGY

Macrophages differentiate from blood monocytes

In 1884, Ilya Ilyich Mechnikov, an immunologist and pathologist in Russia, identified MΦ. Hereafter, the exploration of this cell type has never waned. Regarding the origin of MΦ, the mononuclear phagocyte system arises from hematopoietic stem cells in the bone marrow and from progenitors in the embryonic yolk sac[10], as well as from fetal liver during early development. As early as 1980, it was verified by using
the Chediak-Higashi marker that both interstitial and intraalveolar MΦ of the lung are derived from bone marrow precursor cells\(^{11}\). The family of mononuclear phagocytes consists of monocytes (Mo), MΦ, osteoclasts and DCs.

Granulocyte-macrophage colony stimulating factor (GM-CSF) is a major factor that can promote hematopoietic stem cell differentiation into granulocyte-monocyte cells, promonocytes and Mo\(^{12,13}\). Thereafter, Mo circulate in the blood stream in different types of tissues (the environment with different types of tissues controls the differentiation and maturation of resident MΦ by several molecular mechanisms\(^{14-19}\)), a part of the blood MΦ undergo maturation, adapt to their local microenvironment and turn into various resident MΦ. Resident MΦ may remain as relatively long-life span cells, although they usually cease to proliferate\(^{21,22}\). The remaining blood Mo differentiate into free MΦ, migrating between diverse tissues like amoebae.

To be more rigorous, some researchers further showed that Mo in the bone marrow can be classified as Ly6\(^{+}\) Mo and Ly6\(^{−}\) Mo by their expression of Ly6C/Gr1, CCR2 and CX3CR1. Ly6\(^{−}\) Mo express high levels of Ly6C/Gr-1, CCR2 and CD62L, but low levels of CX3CR1. CCR2 is a chemokine receptor, which is essential for Ly6\(^{+}\) Gr-1+CX3CL1 Mo to enter the circulation. Ly6\(^{+}\) Mo express low levels of Ly6C/Gr1, CCR2 and CD62L but high levels of CX3CR1\(^{21,22}\). Ly6\(^{+}\) Mo are proposed to be the precursors of resident MΦ\(^{4,22}\), but there are some conflicts about this hypothesis if the Mo entering the blood stream rely on expressing CCR2, and there is no abundant evidence to support this conclusion. Moreover, MΦ differentiate from blood Mo, a finding that has been challenged recently. Some researchers have suggested that blood Mo contribute little to MΦ in the steady state, and emerging evidence indicates that resident MΦ can undergo self-renewal\(^{23}\). However, other researchers demonstrated that blood Ly6\(^{−}\) Mo are responsible for turning into resident MΦ because they convert into Ly6\(^{+}\) Mo and can return to the bone marrow, differentiating into Ly6\(^{−}\) Mo\(^{21,22}\). This explanation may be helpful to understand the origin of resident MΦ.

**Biologic features and common functions of macrophages**

The volume of MΦ is 5-10 times that of Mo, and they have more organelles (especially lysosomes), folds and pseudopodia. Resident MΦ are widely distributed throughout the body with distinctive phenotypes - for example, dust cells in lung, Langerhans cells in skin, histiocytes in connective tissue, Kupffer cells in the liver, mesangial cells in the kidney and microglial cells in the central nervous system.

A considerable amount of MΦ exists in the intestine, and specific markers expressed by MΦ can be used to study the heterogeneity. For instance, the F4/80\(^{24}\) antigen and macrosialin in mice are proven to be useful markers in most of the tissues to define the distribution of MΦ, while several antigens such as sialoadhesin, a lectin-like receptor for sialylated glycoconjugates, are particularly strongly present in populations of MΦ in lymphoid organs that do not express F4/80 or CD68. In humans, the CD68 antigen (the human homolog of macrosialin) is widely found in MΦ expressing EMR2 (the human homolog of F4/80)\(^{20}\).

Presently, many promising markers are awaiting identification, and some detected materials have already generated new hypotheses. For example, matrix metalloproteinase-9, produced by MΦ in the early phase of mouse peritonitis, may be used as an inflammatory marker\(^{25}\). In addition, the protein dehydrogenase/reductase-9 was identified as a specific and stable marker of human regulatory MΦ (Mregs)\(^{26}\), which contributed greatly to the existing body of knowledge on immunosuppressive therapy.

MΦ can be classified as M\(_1\) and M\(_2\), functionally within the Mregs. M\(_1\) MΦ produce high interleukin (IL)-12 and low IL-10, while M\(_2\) MΦ show the opposite trend. Additionally, M\(_1\) MΦ express IL-13\(_{1,1}\), but M\(_2\) MΦ do not\(^{27}\). A recent study has shown that a novel marker, MS4A4A (a member of the membrane-spanning 4A gene family), is only expressed in M\(_2\) MΦ - that is, MS4A4A might be a surface marker of M\(_2\) MΦ\(^{28}\). M\(_2\) MΦ were largely mysterious in the past, while the importance of M\(_2\) MΦ in mucosal biology has been appreciated for decades; the immune regulatory function of M\(_2\) MΦ has only begun to be understood in the last few years. Additionally, their differentiation, as well as their differences from M\(_1\) MΦ in cell biology, will become clearer in the future. Thus, regarding Mregs, it is also important that they are activated by different pathways and play diverse roles in the immune system, which will be described below.

MΦ, "big eaters", are named after their major function: phagocytosis, involving the uptake of particulate materials (> 5.0 μm) by opsonic (Fc receptors and C3b receptors) or non-opsonic receptors such as mannose receptors, scavenger receptors, formyl-methionine-leucyl-phenyalanine, and pattern recognition receptors (PRRs), especially the Toll-like receptors (TLRs). With the existence of these receptors, MΦ can participate in innate immunity and adaptive immunity (Figure 1).

MΦ dispose of approximately 2 × 10\(^{11}\) erythrocytes a day and clear damaged or dying cells\(^{20}\). Activated MΦ can recognize microorganisms that break into the epithelial or mucosal barriers with their special/non-special receptors and stretch the pseudopodia to swallow these microbes, followed by their digestion by oxygen-dependent/independent pathways in phagolysosomes. Beyond that, MΦ can be activated by IL-8 and release chemotactic factors and mediators of inflammation (IL-1, IL-6, IL-12 and tumor necrosis factor (TNF)-α), which recruit neutrophils to the inflammatory site.

The neutrophils produce bactericidal compounds,
causing the liquefaction of tissue and formation of pus to eliminate the invading as well as missing pathogens. To complement MΦ, neutrophils secrete several preformed proteins stored in the granules, such as lactoferrin, lipocalin, lysozyme, IL-37, defensins and myeloperoxidase (converts H₂O₂ to hypochlorous acid) [20]. However, MΦ are not so bellicose. To maintain homeostasis of innate immunity, several self-regulative mechanisms restrain inflammation. NK cells inhibit the activation of MΦ by releasing IFN-γ or reducing the number of overactive MΦ by cytotoxicity. IL-1β, IL-10 and transforming growth factor (TGF-β), produced by MΦ, are responsible for down-regulating the innate immune response. Moreover, the dead neutrophils are phagocytosed by mononuclear phagocytes, and lipoxins, protectins and resolvins contribute to the restoration of normal function [20].

In adaptive immunity, MΦ are an antigen-presenting cell type, like DCs. In the marginal sinus of a lymphoid organ, after digestion, MΦ present fragments at the cell surface on MHCII molecules. Indeed, MΦ are less effective than DCs in antigen presentation to naïve T cells because they only express appropriate costimulatory molecules (e.g., CD40, CD80 and CD86) following infection or contact with microbial productions. However, DCs express high levels of MHCII molecules as well as costimulatory molecules. In fact, several microbial productions promote the expression of MHCII molecules and costimulatory molecules in MΦ, which probably enhance the autoimmune response [29].

Gut-associated lymphoid tissues, including dispersed and aggregative tissues, are the primary part of the intestinal immune system [30-32]. The latter type is represented by Peyer's patches (PPs), settled in the LP of the appendix and small intestine, and the solitary lymphoid follicles, widely distributed in the intestinal LP [33,34]. The PPs look like an arch, and they are covered by follicle-associated epithelium, which involves special cells named microfold/membranous cells (M cells) [34,35]. T cells, B cells [36], DCs and MΦ exist in a pocket-like structure outside the base of M cells. M cells efficiently uptake antigens. However, instead of processing and presenting antigens, they are only responsible for transporting antigens to epithelial cells or antigen presenting cells (DCs and MΦ) to induce the adaptive immune response. It has been certified that the cell-bound antigen transportation can affect mucosal tolerance with the participation of

![Diagram](image_url)

**Figure 1  Receptors or molecules of resident and inflammatory macrophages.** MΦ express opsonic (FcR and C3bR) or nonopsonic receptors, such as CKRs, MRs, SRs, FMLP and TLRs, as well as express high levels of MHCII. However, there are some differences between resident MΦ and inflammatory MΦ. Resident MΦ (left) do not express high levels of costimulatory molecules such as CD40, CD80 and CD86, and present hyporesponsiveness to TLRs to suppress inflammation. However, inflammatory MΦ (right) show the opposite trend. The PAMPs lead to inflammation by connecting with hyperresponsive TLRs. CKR: Cytokine receptor; FMLP: Formyl-methionine-leucyl-phenylalanine; MR: Mannose receptor; MΦ: Macrophages; PAMP: Pathogen-associated molecular pattern; SR: Scavenger receptor; TLR: Toll-like receptor.
regional lymph nodes\(^{[41]}\).

Mφ: Mφ or classically activated Mφ develop in cell-mediated immune responses, which are mainly driven by interferon (IFN)-\(\gamma\) and TNF. IFN-\(\gamma\) can be produced in innate immunity and adaptive immunity. In the former, NK cells are important, but the production of IFN-\(\gamma\) in NK cells is too transient for the persistence of this population of Mφ. Consequently, it is necessary to depend on the adaptive immune response; T helper (Th) 1 cells release sustainable IFN-\(\gamma\) and induce classical activated Mφ to kill the microbes indiscriminately\(^{[42]}\).

Endogenously produced IFN-\(\gamma\) is another factor that can replace IFN-\(\gamma\) to activate classically activated Mφ\(^{[43]}\). Mi: Mφ are the major component of host defense. They produce pro-inflammatory cytokines (e.g., IL-1, IL-6 and IL-23) and associate with Th cells, but it has been reported that their connection with Th17 cells, which produce IL-17, results in serious tissue damage. Thus, their over-activation may be the cause of autoimmune diseases\(^{[42]}\).

Mφ or alternatively-activated Mφ are produced during the innate or adaptive immune response. Basophils and mast cells produce innate IL-4, one of the first innate signals released during tissue injury, and IL-4 turns the resident Mφ into this population of cells to promote wound healing. IL-4 can also be released in adaptive immune responses that can be thought as particularly important pathways to develop and persist the alternatively-activated Mφ\(^{[42]}\).

In addition, the Th2-type immune responses have been documented to work at the intestinal mucosal surface to respond to the disturbances by cytokines, such as IL-4 and IL-13\(^{[44]}\). However, compared with M\(\text{ii}\): Mφ, there is no sufficient evidence to show that M\(\text{ii}\): Mφ directly participate in the bactericidal activities, but they do have indirect regulatory effects\(^{[45]}\), which may explain why it is hotly debated in the field of neoplasms\(^{[46­56]}\), fibrosis\(^{[57­60]}\), metabolic syndrome (might relate to insulin resistance)\(^{[61­65]}\) and intestinal autoimmune diseases.

Mregs are a type of immunosuppressive cells, which have been illustrated comprehensively by Mosser et al\(^{[42]}\). Those authors summarized the mechanisms of producing Mregs in innate and adaptive immune responses and the stimuli of these processes. In addition, they mentioned that Mregs produce IL-10 and decrease the production of IL-12 to dampen inflammation. However, their helpful antiinflammatory function might be exploited by parasites to safely survive in the host's defense, which is an interesting point and powerful evidence to confirm the role of Mregs in the immune system.

To summarize, Mφ are extraordinarily complicated in their structure and functions. On the one hand, they are pioneers of pathogen defense in vivo, and one of the regulators that control the immune responses. On the other hand, they can be considered a bridge between innate immunity and adaptive immunity. It has been proven that they are very important in diseases such as asthma\(^{[66­70]}\), atherosclerosis\(^{[71­76]}\), retinopathy\(^{[77­80]}\), neoplasm and autoimmune diseases.

Mφ PLAY A FUNCTIONAL ROLE IN INTESTINAL HOMEOSTASIS

General characteristics of intestinal Mφ

The differentiation of intestinal Mφ rely on intestinal epithelial cells, which have been proven by an extracorporeal three-dimensional coculture model\(^{[81]}\), Mi: Mφ are found in the intestinal tract of all mammals, both in the mucosa and deeper layers\(^{[82]}\). They are found mostly frequently in the LP and produce PGF2 to replenish deficient epithelial cells\(^{[23]}\). Several studies have summarized a rule about the quantity of intestinal Mφ, as follows: in different parts of the intestine, the numbers of Mφ correlate with the quantity of bacteria.

An experiment provided the supporting evidence by recording the weight of each mouse organ or tissue and calculating their F4/80 antigen levels. The total F4/80 antigen levels in the small bowel were 1.3 × 10\(^7\) and 1.4 × 10\(^7\) in the large bowel. In the intestine of germ-free mice, the numbers of Mφ are decreased\(^{[24]}\), likely indicating that the pathogen defense should also be the basic function of intestinal Mφ.

The general markers of Mφ have been mentioned above. Regarding intestinal Mφ, they can be recognized by their unique markers. Resident Mφ in the healthy mouse colon are F4/80\(^+\), CD11c\(^+\), MHC Ⅱ and CD68\(^+\) (also found in humans\(^{[83]}\)). CD11c\(^+\), CD11c\(^+\), CD103\(^+\) and Siglec F\(^{[82]}\). Unlike resident Mφ in other tissues, the highly expressed CX3CR1 is unique. Furthermore, the intestinal Mφ express CD13\(^{[84]}\), CD14 and CD70, and they can be subdivided according to their size\(^{[85]}\). Previously, it was difficult to distinguish between intestinal DCs and Mφ; however, a small population of mucosal Mφ has recently been found to express CD11c, which is a specific marker of DCs. The F4/80\(^+\), CD11b\(^+\), and CD68\(^+\) cells are more likely to be Mφ rather than DCs. They do not present antigens to naïve T cells, and only the CD103\(^+\)CX3CR1 cells are classical DCs\(^{[82,86­90]}\). These findings resolved a few puzzles concerning intestinal DCs and Mφ-like cells with the emergence of a possible hypothesis about the relationship between intestinal Mφ and DCs.

Differences between macrophages in the intestine and other tissues are illustrated in Figure 1. Unlike Mφ in other tissues, resident Mφ\(^{[91]}\) in the healthy intestine do not express high levels of costimulatory molecules, such as CD40, CD80 and CD86\(^{[83]}\), and they do not up-regulate costimulatory molecules or induce a respiratory burst to exterminate microbes\(^{[82,84]}\). Additionally, their responses to TLR ligands are unexpected\(^{[82,90]}\). TLRs are membrane glycoproteins located at the cell surface or within endosomes. They have an extracellular region to bind ligand and an ectoplasmic domain to trigger the
intracellular signaling cascade. They can form hetero- or homodimers with each other, or complex with other receptors to recognize a wide range of microbes.

In general, with the TLRs, MΦ can be activated through many pathways mediated by MyD88, TRIF and NF-κB.[20] It is widely accepted that TLRs are the most characteristic PRRs. However, the intestinal resident MΦ do not respond to TLR ligands and produce proinflammatory cytokines or chemokines, such as IL-1, IL-6, IL-12, IL-23, TNF-α and CXCL10[82,91], which can be considered the inertia of mucosal MΦ. It has been conjectured that such is likely due to the absence of TLRs and other receptors (NOD-1/NOD-2) or malfunction of signaling pathways (via inhibitors or other mechanisms)[96,98]. However, this does not mean that the intestinal resident MΦ do not express TLRs or that TLRs are not necessary. In fact, they are essential to protect the intestinal epithelium under pathological circumstances[97,99,100].

These differences between intestinal mucosal MΦ and their homogeneity in other tissues reveal that they are more likely to control inflammation and maintain homeostasis in healthy individuals. However, what will occur if the balance has become broken?

**Intestinal MΦ change dramatically under different situations**

It is less rigorous to use the word “change”[101] in the subtitle because there is little detail to describe that the intestinal resident MΦ change into inflammatory MΦ (classical MΦ) under pathological circumstances with the changes in the environment, or that these two types of MΦ coexist in healthy intestine, working respectively. Nonetheless, there is another possibility. A credible concept has been explained[21] involving CD14–CD16+ Mo, which can be considered to enter the intestinal LP only in a CCR2-dependent[102] manner and turn into the resident CD14+MHCII+CD163+CD64+ MΦ or inflammatory CD14+MHCII+CD163–CD64+ MΦ in different circumstances. However, confusion concerning the relationship between CD14–CD16+ Mo and Ly6C/h Ly6C Mo has emerged and remains to be directly described.

It is clear that intestinal resident MΦ produce antiinflammatory cytokines, especially IL-10 and TGF-β[6,84,103-111], whereas inflammatory MΦ work at the inflammatory site and have strong bactericidal activity, as explained above. In healthy intestine, IL-10 is produced by mucosal MΦ themselves and is a component of T cells[111]. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide increase the production of IL-10 by mucosal MΦ in vitro and in vivo[113]. IL-10 prevents the NF-κB pathway, and inhibiting the autocrine/paracrine production of IL-10 reverses TLR unresponsiveness in MΦ[82]. Maintaining Foxp3 expression of regulatory T cells (Tregs) has been reported as one of the important functions of IL-10 produced by MΦ[114]. CD4+Foxp3+ Tregs greatly contribute to the immune regulatory networks with the complement of other T cells and B cells, maintaining intestinal homeostasis[115]. Recently, research[107] on Citrobacter rodentium-infected mice with cell type-specific deletion of IL-10 demonstrated that IL-10 prevents excessive inflammation in acute bacterial infection by controlling IL-23[116,117] production to limit innate immunity. Another study indicated that the deficiency of IL-10 results in stable chromatin alterations in intestinal MΦ[118]. These results showed that IL-10 indeed plays a critical role in limiting inflammation.

Another factor for antiinflammation is TGF-β. Intestinal resident MΦ express high levels of TGF-β receptors and show constitutively-active TGF-β signaling[82]. TGF-β also connects with Foxp3, expressed by Tregs, and CD4+Foxp3+ Tregs decrease the ability of mucosal MΦ to activate and translocate NF-κB[115]. Intestinal resident MΦ do not respond to TLR ligands with the existence of TGF-β[82]. In contrast to IL-10, their production in murine MΦ is inhibited by VIP[111]. Moreover, the expression of Smad7 (a member of the Smad family that mediates a pathway for TGF-β signaling and activates inflammatory MΦ, a finding that was demonstrated in an experiment of necrotizing enterocolitis MΦ)[110].

Currently, the study of CD200 for antiinflammation has received less attention. CD200L is a member of the protective system, with the ability to restrain the activity of MΦ. Inhibitory signaling of CD200L is triggered by the interaction with CD200 in nonhematopoietic cells as well as MΦ[20]. This process protects tissues from severe damage. A study reported that knock-out of CD200 or CD200R1 produces MΦ hyperactivity and autoimmune diseases[119]. Enlightened by this, it is possible to assume CD200 maintains intestinal homeostasis. There are some relevant studies in the respiratory system[120], but the existing evidence in the intestine remains insufficient.

The enteric nervous system (ENS) plays a crucial role in controlling gastrointestinal physiology and interacting with microbes and immune cells, functions that have been explored for decades. Accumulating evidence indicates they closely contact MΦ. The development of CX3CR1+MHCII+CD11b+CD11c+CD103+ muscularis MΦ (MMs) requires CSF1, and enteric neurons selectively express bone morphogenetic protein (BMP; expressed by MMs) receptor 2, which produces CSF1. By contrast, the expression of BMP2 activates enteric neurons. The correlation of MMs and ENS contributes to gut motility[121]. Additionally, MMs have been found to express tissue-protective and wound-healing genes resembling M: MΦ, reacting in intestinal infection[122].

More importantly, neurotransmitters are essential for neuronal immune control. VIP is known to exhibit...
antinflammatory effects, depending on promoting the production of IL-10. Nitric oxide is well known for its antimicrobe ability in the respiratory burst. However, it suppresses excitability in neurons[123] and influences ENS during intestinal inflammation[91]. Interestingly, serotonin (5-HT), which was considered a trigger of inflammation, has been demonstrated to act, indirectly, on MMs by 5-HTT receptors in neurons and to stimulate an antinflammatory cascade in MΦ. It has been indicated that 5-HT7 and 5-HT1 are related to the development of M1 and M2 MΦ[91]. In addition, γ-amino butyric acid has been suggested to have an immunosuppressive effect on resident MΦ of the central nervous system[61]. However, in the intestine, it remains unclear. It is worth investigating the functions of ENS and how they act on MΦ to understand the gut immune system and associated disease treatments in the future.

Current views about intestinal MΦ
First, Kennichi et al[123] provided an exhaustive experimental result concerning LP-resident CD169⁺ MΦ that mainly persist in secondary lymphoid organs. They indicate that CD169⁺ MΦ reside at the bottom-end of the LP microenvironment, far away from the epithelium-LP border. Most importantly, the CD169⁺ MΦ recruit inflammatory monocytes by producing CCL8, selective depletion of CD169⁺ MΦ and anti-CCL8 antibody promotion of dextran sulfate sodium-induced colitis in mice. The comparison of CD109 and CD109⁺ MΦ led to an interesting hypothesis. Unlike CD109⁺ MΦ, CD109⁺ MΦ are located in a region distant from the perimeter where they can be interrupted by commensal bacteria and dead epithelial cells, and they can directly release CCL8 into the systemic circulation in the vascular-rich environment. CD109⁺ MΦ probably respond to the collapse of the frontline defense - i.e. they can be considered as a “conservation corps” in the intestine (Figure 2).

Second, MΦ struggle for attention. As another regulative population, MΦ produce IL-10 and express CD163 and CD206 lectin receptors. They do not produce proinflammatory mediators with signals of stimulation. Certainly, they produce tissue-repairing factors, such as vascular endothelial growth factor (VEGF), actin and metalloproteinases, due to their function in wound healing. MΦ are MHCII⁺, which may be helpful in exploring their potential in bactericidal activities[82,83,124,125]. Unlike MΦ, Mregs express high levels of costimulatory molecules, such as CD40, CD80 and CD86, to submit antigens to T cells more effectively[42], highlighting the hypothesis that the regulation of MΦ in the intestine might be different from that of Mregs. However, the antinflammatory function of Mregs mentioned above has not been directly verified in the intestine. Therefore, we are unsure about the role of Mregs in intestinal homeostasis, and some questions remain concerning the meaning of the difference between M1 MΦ and Mregs (Figure 2).

Finally, a novel finding[126] concerning GPBAR1 (a G protein-coupled receptor for secondary bile acids) suggests that GPBAR1 is essential to maintain intestinal immune homeostasis by regulating M1/M2 MΦ. BAR501 (a small-molecule stimulus of GPBAR1) contributes to this regulatory process, depending on the production control of IL-10. Absence of the GPBAR1 gene causes the recruitment of M1 macrophages and severe inflammation in the colon. Exposure to BAR501 leads to the increased expression of IL-10 and TGF-β mRNA, and percentage of CD4⁺Foxp3⁺ cells. Based on this study, GPBAR1 deserves attention for its potential to protect intestinal health (Figure 2).

MΦ AND GASTROINTESTINAL DISORDERS

MΦ and IBD
According to the mechanisms of intestinal MΦ in maintaining homeostasis, any defect of the antinflammation system may bring the reduction of immune tolerance, resulting in IBD. In 1998, it was found that intestinal MΦ displayed low expression of class II MHC molecules in mouse colitis[147]. A hypothesis arose from this study that there could be dysfunction of MΦ participating in adaptive immune responses when inflammation occurs.

From the origin of MΦ, emerging evidence suggests that GM-CSF plays a central role and has a protective effect in human CD and acute colitis by activating specific MΦ[128,129]. Classical CD14⁺CD16⁻ Mo differentiate into large numbers of inflammatory MΦ in the inflamed mucosa of patients with CD[21]. CD14⁺ Mo in the mucosa from IBD patients increase the production of TGF-β[128,131], IL-1β and IL-6, and enhance respiratory burst activity[21]. Moreover, IL-10 knock-out mice develop spontaneous IBD[81]. An intrinsic resistance to TGF-β receptor signaling has been shown in the mucosa from patients with CD[130]. CD4⁺Foxp3⁺ T cells fail to protect the intestine from chronic inflammation without IL-10- and TGF-β-independent mechanisms[134]. MΦ have been certified to be activated by the Wnt signaling pathway, which is associated with UC[133]. These studies showed that intestinal MΦ are of great value for IBD. Following this result, promising treatments for IBD, such as CD109⁺ MΦ Tregs and GPBAR1, can be considered new therapeutic targets.

MΦ are clearly associated with IBD, but there remain a few puzzles regarding some details. The first study[134] observed that RoRγ T cells in intestinal mucosa (ILCs; the primary source of GM-CSF in the gut) promote MΦ to respond to the microbial signals and produce IL-1β, which enhances inflammation. By contrast, another study[135] discovered that with the regulation of RoRγ T ILCs, MΦ promote a negative feedback
pathway through the activation of IL-22 production, which might be protective. Indeed, the quantity of RoRγT+ ILCs could increase in human CD. This finding inspires the question of whether the possibility exists that a portion of MΦ still tries to restore intestinal homeostasis when the intestine is trapped in a vicious cycle for inflammatory macrophages. The second item concerns CD200R1 mentioned above. Knock-out of CD200 results in MΦ hyperactivity in vitro, but CD200R1 knock-out mice have normal intestinal MΦ populations, and they neither develop spontaneous IBD nor become more susceptible to colitis induced by the dextran sulfate sodium model [82]. This indicates that CD200R1 may not be as important as we had previously considered, but the reasons remain unclear.

**MΦ and gastrointestinal tumors**

Since the end of the last century, many studies have certified the connection between MΦ and tumors in various systems. There are considerable numbers of investigations concerning tumor-associated macrophages (TAMs). They promote immunosuppression, tumor immune evasion [136], tumorigenesis, tumor metastasis and angiogenesis as well as invasion by releasing various cytokines and inflammatory mediators, such as IL-6, IL-10, TGF-β, CCL2, CCL17, VEGF and cathepsins [137]. However, different populations of TAM have different functions. M1 MΦ have been confirmed to recognize and clear tumor cells, a function that is beneficial to health. By contrast, the development and movement of tumors benefit from M2 MΦ. TAMs are one of the promising targets of tumor therapy, especially M2 MΦ. Gut tumors are also included. We provide more details about TAMs and references in Box 4 to further illustrate the relationship between TAMs and tumors.

Similar to other MΦ, TAMs arise from hematopoietic stem cells in the bone marrow and from progenitors in the embryonic yolk sac. With different environmental signals, Mo differentiate into distinctive macrophages [137,138]. Tumor signals contribute to the development of TAMs. Mantovani et al [139] summarized the signals associated with TAMs. For example, lactic acid, CCL2, CSF1, VEGF and TGF-1 from tumor cells, IL-1β from tumor-associated fibroblasts, and IL-10 from Tregs, all can drive TAMs into tumor-promoting MΦ. Moreover, they also list the products of TAMs which have different functions. For instance, IL-6, MFG-E8 and osteopontin from TAMs can active tumor stem cells; TAMs produce epidermal growth factor to promote tumor growth, invasion and metastasis. Nitric oxide and reactive oxygen species can be released to destroy tumor cells. However, they might...
MΦ differentiate from blood Mo. Ly6cβ TLR receptor; TNF: Tumor necrosis factor; VEGF: Vascular endothelial growth factor. as well as that of Ly6Cβ (green arrow). Regarding MΦ and intestinal immunity, many details remain unclear - for instance, the functions of RoRγ to inflammation (orange arrows). In addition, MIL-12, and IL-23, and activate effective T cells with several specific receptors, such as TLR, as well as induce respiratory burst (green arrow). In healthy intestine (left side), resident MΦ are F4/80hi; class II MHC, CX3CR1hi, CD11c+, CD103 and Siglec F. They do not express high levels of costimulatory molecules such as CD40, CD80 and CD86. Their connections with CD4+/Foxp3+ T cells, IL-10 and TGF-β1 are helpful to maintain intestinal homeostasis (green arrows). GPBAR1 is essential to maintain intestinal immune homeostasis by regulating Mφ/MΦ. In inflamed intestine (right side), Mo change into inflammatory MΦ, which produce TNF-β, IL-1, IL-6, IL-12, and IL-23, and activate T cells with several specific receptors, such as TLR, as well as induce respiratory burst (e.g., NO and H2O2 production), leading to inflammation (orange arrow). In addition, MΦ produce tissue-repairing factors such as VEGF, which shows a positive effect in individuals during inflammation (green arrow). Regarding MΦ and intestinal immunity, many details remain unclear - for instance, the functions of RoRγ ILCs and CD200/200R (in blue rectangle) as well as that of Ly6C+ Mo. IL: Interleukin; ILC: Innate lymphoid cell; Mo: Monocytes; MΦ: Macrophages; NO: Nitric oxide; TGF: Tumor growth factor.

Figure 3 Functional role of macrophages in healthy or inflamed intestine. MΦ differentiate from blood Mo. Ly6c+ Mo are proposed to be the precursors of resident MΦ. CD14+CD16+ Mo turn into resident or inflammatory MΦ according to different circumstances via the CCR2 pathway. In healthy intestine (left side), resident MΦ are F4/80hi; class II MHC, CX3CR1hi, CD11c+, CD103 and Siglec F. They do not express high levels of costimulatory molecules such as CD40, CD80 and CD86. Their connections with CD4+Foxp3+ T cells, IL-10 and TGF-β1 are helpful to maintain intestinal homeostasis (green arrows). GPBAR1 is essential to maintain intestinal immune homeostasis by regulating Mφ/MΦ. In inflamed intestine (right side), Mo change into inflammatory MΦ, which produce TNF-β, IL-1, IL-6, IL-12, and IL-23, and activate T cells with several specific receptors, such as TLR, as well as induce respiratory burst (e.g., NO and H2O2 production), leading to inflammation (orange arrow). In addition, MΦ produce tissue-repairing factors such as VEGF, which shows a positive effect in individuals during inflammation (green arrow). Regarding MΦ and intestinal immunity, many details remain unclear - for instance, the functions of RoRγ ILCs and CD200/200R (in blue rectangle) as well as that of Ly6C+ Mo. IL: Interleukin; ILC: Innate lymphoid cell; Mo: Monocytes; MΦ: Macrophages; NO: Nitric oxide; TGF: Tumor growth factor; TLR: Toll-like receptor; TNF: Tumor necrosis factor; VEGF: Vascular endothelial growth factor.

result in genetic instability, causing tumor formation. Nevertheless, further studies have indicated that not all the macrophages that have emerged into the tumor microenvironment are tumor promoting.

M1: MΦ (having antitumor function) can recognize tumors and kill tumor cells by the cytotoxic effect, representing a double-edged sword. They have been verified as an independent predictor of survival time in patients with non-small cell lung cancer. M2: MΦ have a protumor function. They promote the metastasis of K7M2 wild-type osteosarcoma cells in mice. Additionally, all-trans retinoic acid dampens the production of IL-13 or IL-14 (from M2 m MΦ) to inhibit the metastasis of osteosarcoma. CHI3L1, a protein secreted by M2 MΦ, promotes the metastasis of gastric and breast cancer cells. In addition, it was confirmed that patients with peritoneal dissemination in gastric cancer have more M2 MΦ and low expression of M1-related messengers. MFG-E8, a powerful angiogenic factor, is induced by bone marrow-derived mesenchymal stromal cells in mice. Attenuated tumor growth and the decreasing function of M2 MΦ can be found in MFG-E8-deficient mice, which represent M2 MΦ that contribute to tumor angiogenesis; whether the correlation of M2 MΦ and MFG-E8 is parallel or antiparallel should be further clarified.

Above all, TAMs have advantages and disadvantages to both human physiology and tumors. They are members of our defensive line, but they are also tumor helpers. Compared with the favorable contributions of TAMs, such as M1 MΦ in tumor resistance, the promising therapeutic targets they provide might be more useful. In the 1990s, some scientists systematically revealed that TAMs were worth exploring for antitumor therapy, and more and more findings were uncovered during the last 50 years. On the one hand, TAMs are hopeful antitumor targets; on the other hand, as Mantovani and Allavena illustrated, the mechanisms of TAMs in tumor development and antitumor processes are intricate, which limits researchers’ ability to find the antitumor target precisely. This phenomenon is the yin-yang of antitumor therapy and the challenge of future antitumor studies.

Several studies have presented recent research progress in gastrointestinal tumors. First, tumor angiogenesis and survival in intestinal-type gastric cancer is closely associated with the infiltration of thymidine
phosphorylase-positive MΦ. Therefore, thymidine phosphorylase could be a useful marker for tumor angiogenesis, and the prognosis of intestinal-type gastric cancer. Second, there is a hotspot induced by MΦ. A portion of MΦ, cooperating with TNF, were shown to be recruited to tumors\(^{56,147}\). The macromolecular contrast agent PG-Gd-NIR813 shows a dual magneto-optical imaging probe of tumor-associated MΦ. MΦ show a few new factors have been evaluated as mediators of the development of gastrointestinal tumors, such as MΦ-secreted CHI3L1 protein\(^{53}\) and monocyte chemoattractant protein\(^{-1,148}\). All are likely to become novel approaches for antitumor therapy.

**CONCLUSION**

In summary (Figure 3), MΦ with their various receptors act as sentinels in innate immunity and adaptive immunity. In healthy intestinal mucosa, they are indispensable to suppress inflammation and play an essential role in maintaining homeostasis by producing many inhibitors, such as IL-10 and TGF-β. However, they show strong bactericidal activities. Intestinal resident MΦ create a harmonious environment for commensal bacteria and their host. Any defect in keeping this balance can reduce immune tolerance, causing acute tissue damage or chronic autoimmune diseases, explaining their close association with IBD. New findings concerning intestinal MΦ and IBD, as well as tumors, can be very helpful for studies and disease treatments. Meanwhile, there are many details awaiting clarification as well as many unresolved issues.

**ACKNOWLEDGMENTS**

We wish to thank Prof. Zhang Min (School of Biological Engineering, Capital Medical University) for her contribution in polishing the language of this manuscript.

**REFERENCES**

1. Sartor RB. Microbial influences in inflammatory bowel diseases. *Gastroenterology* 2008; 134: 577-594 [PMID: 18242222 DOI: 10.1053/j.gastro.2007.11.059]
2. Macpherson AJ, Harris NL. Interactions between commensal intestinal bacteria and the immune system. *Nat Rev Immunol* 2004; 4: 478-485 [PMID: 15173826 DOI: 10.1038/nri1373]
3. Tang L, Cheng CY, Sun X, Pedicone AJ, Mohamadzadeh M, Cheng SX. The Extracellular Calcium-Sensing Receptor in the Intestine: Evidence for Regulation of Colonic Absorption, Secretion, Motility, and Immunity. *Front Physiol* 2016; 7: 245 [PMID: 27458380 DOI: 10.3389/fphys.2016.00245]
4. Bain CC, Mowat AM. Macrophages in intestinal homeostasis and inflammation. *Inflamm Res* 2014; 63: 102-117 [PMID: 24942685 DOI: 10.1111/irn.12192]
5. Altmeyer S, Zienek I, Vihajen W, Scharek-Tedin L. The expression of NKG2D on porcine IEL and its possible relation to the adaptive intestinal immune system. *Vet Immunol Immunopathol* 2017; 187: 89-95 [PMID: 28494934 DOI: 10.1016/j.vetimm.2017.03.005]
6. Goodyear AW, Kumar A, Dow S, Ryan EP. Optimization of murine small intestine leukocyte isolation for global immune phenotype analysis. *J Immunol Methods* 2014; 405: 97-108 [PMID: 24508527 DOI: 10.1016/j.jim.2014.01.014]
7. Weitkamp JH, Rosen MJ, Zhao Z, Koyama T, Geem D, Denning TL, Rock MT, Moore DJ, Halpern MD, Matta P, Denning PW. Small intestinal intraepithelial TCRγδ T lymphocytes are present in the premature intestine but selectively reduced in surgical necrotizing enterocolitis. *PLoS One* 2014; 9: e99042 [PMID: 24905458 DOI: 10.1371/journal.pone.0099042]
8. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. *Curr Gastroenterol Rep* 2010; 12: 319-330 [PMID: 20703838 DOI: 10.1007/s11894-010-0131-2]
9. Johansson ME, Hansson GC. Mucus and the goblet cell. *Dig Dis* 2013; 31: 305-309 [PMID: 24246979 DOI: 10.1159/0003545683]
10. Takata K, Kozaki T, Lee CZW, Thron MS, Otsuka M, Lim S, Utami KH, Fidan K, Park DS, Malleret B, Chakarov S, See P, Low D, Low G, Garcia-Miralles M, Zeng R, Zhang J, Goh CC, Gul A, Hubert S, Lee B, Chen J, Low I, Shadman NB, Lum J, Wei TS, Mok E, Kawanishi S, Kitamura Y, Larbi A, Poidinger M, Renia L, Ng LG, Wolf Y, Jung S, Öndert T, Newell E, Huber T, Ashihara E, Garel S, Pouladi MA, Ginhoux F. Induced-Fluoropotent-Stat-Cell-Derived Primitive Macrophages Provide a Platform for Modeling Tissue-Resident Macrophage Differentiation and Function. *Immunity* 2017; 47: 183-198.e6 [PMID: 28723550 DOI: 10.1016/j.immuni.2017.06.017]
11. Johnson KJ, Ward PA, Striker G, Kunkel R. A study of the origin of pulmonary macrophages using the Chédiak-Higashi marker. *Am J Pathol* 1980; 101: 365-374 [PMID: 7001909]
12. Fuad MB, Robert MN. Allergy and Immunology of the Upper Airway. In: Flint PW Haughey BH, Lund V, Niparko JK, Robbins KT, Thomas JR, Lesperance MM, editor Cummings Otolaryngology, 6th ed. Philadelphia, PA, US: Elsevier Saunders, 2015: 593-625
13. MacDonald KP, Palmer JS, Cronau S, Seppanen E, Oliver S, Raffelt NC, Kuns R, Pettit AR, Clouston A, Wainwright B, Brantsteller D, Smith J, Paxton RJ, Cerretti DP, Bonham L, Hill GR, Hume DA. An antibody against the colony-stimulating factor receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. *Blood* 2010; 116: 3955-3963 [PMID: 20682855 DOI: 10.1182/blood-2010-02-266296]
14. Dubertret L, Breton-Gorius J, Fosse M, Touraine R. A cytochemical marker for epidermal differentiation, Langerhans cells, skin resident macrophages and mitochrondria. *Br J Dermatol* 1982; 107 Suppl 23: 96-100 [PMID: 7138784]
15. Hoefsmit EC, Schadee-Eestermans HL, BeeLEN RH. The development of the resident pattern of endogenous peroxidase activity in mouse peritoneal macrophages coincides with the expression of the differentiation antigen F4/80. A combined method for immunoperoxidase labeling and endogenous peroxidase cytochemistry. *J Histochem Cytochem* 1986; 34: 633-640 [PMID: 3517147 DOI: 10.1177/34.5.3517147]
16. Iwama A, Wang MH, Yamaguchi N, Ohno N, Okano K, Sudo T, Takeya M, Gervais F, Morissette C, Leonard EJ, Suda T. Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages and gastrointestinal disorders. *Immunity* 2017; 47: 183-198.e6 [PMID: 28723550 DOI: 10.1016/j.immuni.2017.06.017]
17. Johnson KJ, Ward PA, Striker G, Kunkel R. A study of the origin of pulmonary macrophages using the Chédiak-Higashi marker. *Am J Pathol* 1980; 101: 365-374 [PMID: 7001909]
18. Fowler MB, Robert MN. Allergy and Immunology of the Upper Airway. In: Flint PW Haughey BH, Lund V, Niparko JK, Robbins KT, Thomas JR, Lesperance MM, editor Cummings Otolaryngology, 6th ed. Philadelphia, PA, US: Elsevier Saunders, 2015: 593-625
19. MacDonald KP, Palmer JS, Cronau S, Seppanen E, Oliver S, Raffelt NC, Kuns R, Pettit AR, Clouston A, Wainwright B, Brantsteller D, Smith J, Paxton RJ, Cerretti DP, Bonham L, Hill GR, Hume DA. An antibody against the colony-stimulating factor receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. *Blood* 2010; 116: 3955-3963 [PMID: 20682855 DOI: 10.1182/ blood-2010-02-266296]
20. Dubertret L, Breton-Gorius J, Fosse M, Touraine R. A cytochemical marker for epidermal differentiation, Langerhans cells, skin resident macrophages and mitochondria. *Br J Dermatol* 1982; 107 Suppl 23: 96-100 [PMID: 7138784]
Phagocytes in Immune Defense. In: David M, Jonathan B, David BR, Ivan MR, editor. Immunology. 8 ed. Philadelphia, PA, US: Elsevier Saunders 2013: 123-126

21 Gren ST, Grip O. Role of Monocytes and Intestinal Macrophages in Crohn’s Disease and Ulcerative Colitis. Inflamm Bowel Dis 2016; 22: 1992-1998 [PMID: 27243359 DOI: 10.1097/MIB.0000000000000824]

22 Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82 [PMID: 12871640]

23 Bain CC, Mowat AM. Intestinal macrophages - specialised adaptation to a unique environment. Eur J Immunol 2011; 41: 2494-2498 [PMID: 21952904 DOI: 10.1002/eji.201141714]

24 Lee SH, Starkey PM, Gordon S. Quantitative analysis of total macrophage content in adult mouse tissues. Immunological studies with monoclonal antibody F4/80. J Exp Med 1985; 161: 475-489 [PMID: 3973536]

25 Kolaczkowska E, Arnold B, Odenacker G. Gelatinase B/MMP-9 as an inflammatory marker enzyme in mouse ymzoon peritonitis: comparison of phase-specific and cell-specific production by mast cells, macrophages and neutrophils. Immunobiology 2008; 213: 109-124 [PMID: 18241695 DOI: 10.1016/j.imbio.2007.07.005]

26 Riquelme P, Armodio G, Macedo C, Moreau A, Obermajer N, Brochhausen C, Ahrens N, Kekarainen T, Fandrich F, Curi C, Gregori S, Metes D, Schlitt HJ, Thomson AW, Geissler EK, Hutchinson JA. DHERS Is a Stable Marker of Human Regulatory Macrophages. Transplantation 2017; 101: 2731-2738 [PMID: 28594751 DOI: 10.1097/TP.0000000000001814]

27 Dhakal M, Hardaway JC, Guloglu FB, Miller MM, Hoeman CM, Zaghouani AA, Wan X, Rowland LM, Cacchio JA, Sherman MP, Zaghouani H. IL-13Rα1 is a surface marker for M2 macrophages influencing their differentiation and function. Eur J Immunol 2014; 44: 842-855 [PMID: 24281978 DOI: 10.1002/eji.201334552]

28 Sanyal R, Poley MJ, Zuccolo J, Puri M, Deng L, Roberts L, Zuba S, Storek J, Luider JM, Sundberg EM, Mansoor A, Baigorri E, Forchielli ML, Amodio G, Macedo C, Moreau A, Obermajer N, Doss WF, Tan HD, Takeuchi O, Sugiyama M, Okabe M, Takeda K, Akira S. Role of adaptor TRIF in the MDDR8-independent toll-like receptor signaling pathway. Science 2003; 301: 640-643 [PMID: 12855817 DOI: 10.1126/science.1087262]

29 Edwards JP, Zhang X, Frawirth KA, Mosser DM. Biochemical and functional characterization of three activated macrophage populations. J Leukoc Biol 2002; 80: 1298-1307 [PMID: 14909949 DOI: 10.1189/jlb.0307249]

30 Cordeiro-da-Silva A, Tavares J, Araujo N, Cerqueira F, Tomás A, Kengy Thoo Lin P, Ouaisi A. Immunological alterations induced by polyamine derivatives on murine splenocytes and human mononuclear cells. Int Immunopharmacol 2004; 4: 547-556 [PMID: 15099532 DOI: 10.1016/j.intimp.2004.02.009]

31 Mantovani A, Sozzani S, Locati M, Allavenna P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-555 [PMID: 12140408]

32 Sun S, Cui Y, Ren K, Quan M, Song Z, Zou H, Li D, Zheng Y, Cao J. 8-bromo-7-methoxychrysin Reversed M2 Polarization of Tumor-associated Macrophages Induced by Liver Cancer Stem-like Cells. Anticancer Agents Med Chem 2017; 17: 286-293 [PMID: 26845136]

33 Simões RL, De-Brito NM, Cunha-Costa H, Morandi V, Fierro IM, Roitt IM, Barja-Fidalgo C. Lipoxin A4 selectively programs the profile of M2 macrophage cells which favour control of tumor progression. Int J Cancer 2017; 140: 346-357 [PMID: 27615282 DOI: 10.1002/ijc.30423]

34 Kimura Y, Sumiyoshi M, Baba K, Antitumor and Antimetastatic Activity of Synthetic Hydroxyxystilbenes Through Inhibition of Lynphogeniogenesis and M2 Macrophage Differentiation of Tumor-associated Macrophages. Anticancer Res 2016; 36: 137-148 [PMID: 26722037]

35 Melancon MP, Lu W, Huang Q, Thapa P, Zhou D, Ng C, Li C. Targeted imaging of tumor-associated M2 macrophages using a macromolecular contrast agent PG-Gd-NIR13. Biomaterials 2010; 31: 6567-6573 [PMID: 20537382 DOI: 10.1016/j.biomaterials.2010.05.001]

36 Umemura N, Saio M, Suwa T, Kito H, Yai B, Jonaka K, Ouyang GF, Okada M, Balazs M, Adany R, Shibata T, Takami T. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 2008; 83: 1136-1144 [PMID: 18285406 DOI: 10.1128/JLB.0907207]

37 Van Ginderachter JA, Meerschaut S, Liu Y, Brys L, De Groeve K, Hassanadzhed Ghasabeh G, Raes G, De Baetselier P. Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood 2006; 108: 525-535 [PMID: 16527895 DOI: 10.1182/blood-2005-09-3777]

38 Sica A, Schioppa T, Mantovani A, Allavena P. Tumor-associated macrophages are a distinct M2 polarised population promoting...

Liu YH et al. Macrophages and gastrointestinal disorders
tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006; 42: 717-727 [PMID: 16520032 DOI: 10.1016/j.ejca.2006.01.003]

54 Mantovani A, Saccardi S, Locati M, Schioppa T, Saccani A, Allavena P, Sica A. Infiltration of tumours by macrophages and dendritic cells: tumour-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. *Novartis Found Symp* 2004; 256: 137-145; discussion 146-148, 259-269 [PMID: 15027487]

55 Chen Y, Zhang S, Wang Q, Zhang X. Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CTH131 protein. *J Hematol Oncol* 2017; 10: 36 [PMID: 28143526 DOI: 10.1186/s13045-017-0408-0]

56 Beider K, Bintner H, Leiba M, Gutwein O, Koren-Michowitz M, Oya T, Kanatani Y, Usui I, Bukhari A, Ikutani M, Zhang S, Wang Q, Zhang X. Tumor-recruited M2 macrophages in allergic asthma: an expression signature characterized by heat shock protein pathways. *Hum Immunol* 2010; 71: 144-150 [PMID: 19913588 DOI: 10.1016/j.humimm.2009.11.005]

57 Vissers JL, van Esch BC, Hofman GA, van Oosterhout AJ. Macrophages induce an allergen-specific and long-term suppression in a mouse asthma model. *Respir J* 2005; 26: 1040-1046 [PMID: 16125393 DOI: 10.1183/08031936.05.00089304]

58 Lee TH, Poston R, Godard P, Bousquet J. Macrophages and allergic asthma. *Clin Exp Allergy* 1991; 21 Suppl 1: 22-23 [PMID: 2032150]

59 Godard P, Damon M, Chanez P, Michel FB. Releasability of airway macrophages in bronchial asthma. *Int Arch Allergy Appl Immunol* 1991; 95: 97-101 [PMID: 1937933]

60 Coich C, Zeimbecke A. Macrophages in vascular inflammation and atherosclerosis. *Pflogh Arch* 2017; 469: 485-499 [PMID: 28168325 DOI: 10.1007/s00414-017-1941-y]

61 Neele AE, Van den Bossche J, Hoeksma MA, de Winther MP. Epigenetic pathways in macrophages emerge as novel targets in atherosclerosis. *Eur J Pharmacol* 2015; 763: 79-89 [PMID: 26004034 DOI: 10.1016/j.ejphar.2015.03.101]

62 Lucas AD, Greaves DR. Atherosclerosis: role of chemokines and macrophages. *Expert Rev Mol Med* 2001; 3: 1-18 [PMID: 14585150 DOI: 10.1017/S1462394001003969]

63 Daoud AS, Fritz KE, Jarmolych J, Frank AS. Role of macrophages in regression of atherosclerosis. *Ann N Y Acad Sci* 1985; 454: 101-114 [PMID: 3865603]

64 Wolman M, Gaiton E. [Macrophages and smooth muscle cells in the pathogenesis of atherosclerosis]. *Harefuah* 1976; 90: 400-402 [PMID: 939449]

65 Portillo JC, Lopez Corricio M, Yayo M, Tang J, Sheibani N, Kern TS, Duybark GR, Subauste CS. CD40 in Retinal Mller Cells Induces P2X7-Dependent Cytokine Expression in Macrophages/Microglia in Diabetic Mice and Development of Early Experimental Diabetic Retinopathy. *Diabetes* 2017; 66: 483-493 [PMID: 27474370 DOI: 10.2337/db16-0051]

66 Davies MH, Eubanks JP, Powers MR. Microglia and macrophages are increased in response to ischemia-induced retinopathy in the mouse retina. *Mol Vis* 2006; 12: 467-477 [PMID: 16710171]

67 Naug HL, Browning J, Gole GA, Gobe G. Vitreal macrophages express vascular endothelial growth factor in oxygen-induced retinopathy. *Clin Exp Ophthalmol* 2000; 28: 48-52 [PMID: 11345346]

68 Esser P, Heimann K, Wiedemann P. Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations. *Br J Ophthalmol* 1993; 77: 731-733 [PMID: 2889690]

69 SpooTTl T, Hausmann M, Menzel K, Fibeher G, Herfahr H, Schoermelich J, Bataille F, Rogler G. Role of soluble factors and three-dimensional culture in vitro differentiation of intestinal macrophages. *World J Gastroenterol* 2007; 13: 1032-1041 [PMID: 17373737 DOI: 10.3748/wjg.v13.i13.1032]

70 Mowat AM, Bain CC. Mucosal macrophages in intestinal homeostasis and inflammation. *J Inute Immun* 2011; 3: 550-564 [PMID: 22025201 DOI: 10.1186/000292099]

71 Smith PD, Smythies LE, Shen R, Greenwell-Wild T, Gioiizo M, Wahl SM. Intestinal macrophages and response to microbial encroachment. *Mucosal Immun* 2011; 4: 31-42 [PMID: 20962772 DOI: 10.1038/mi.2010.66]

72 Sheikh SZ, Plevy SE. The role of the macrophage in sentinel responses in intestinal immunity. *Curr Opin Gastroenterol* 2010; 26: 578-582 [PMID: 2077022 DOI: 10.1097/MOG.0b013e32833d47j1]
Liu YH et al. Macrophages and gastrointestinal disorders

Bar-On L, Zignelond E, Jung S. Management of gut inflammation through the manipulation of intestinal dendritic cells and macrophages? *Semim Immunol* 2011; 23: 58-64 [PMID: 21292502 DOI: 10.1016/j.sminimm.2011.01.002]

Cerovic V, Houston SA, Scott CL, Azemunier A, Yrlid U, Mowat AM, Milling SW. Intestinal CD103(-) dendritic cells migrate in lymph and prime effector T cells. *Macosol Immunol* 2013; 6: 104-113 [PMID: 22718260 DOI: 10.1038/mi.2012.53]

Schulz O, Jaesonn E, Persson EK, Liu X, Worbs T, Agace WW, Pabst O. Intestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical dendritic cell functions. *J Exp Med* 2009; 208: 3101-3114 [PMID: 20068524 DOI: 10.1084/jem.20081925]

Kelsall B. Recent progress in understanding the phenotype and function of intestinal dendritic cells and macrophages. *Macosol Immunol* 2008; 1: 460-469 [PMID: 19079213 DOI: 10.1038/mi.2008.61]

Pabst O, Bernhardt G. The puzzle of intestinal lamina propria macrophages. *Blood* 2010; 115: 2107-2111 [PMID: 20853495 DOI: 10.1182/blood-2010-04-296433]

Cerovic V, Bing CC, Mowat AM, Milling SW. Intestinal macrophages and dendritic cells: what's the difference? *Trends Immunol* 2014; 35: 270-277 [PMID: 24794939 DOI: 10.1016/j.ti.2014.04.003]

Wehner S, Engel DR. Resident macrophages in the healthy and inflamed intestinal muscularis externa. *Pilgafr Arch* 2017; 469: 541-552 [PMID: 28236119 DOI: 10.1002/pilla.20744]

Mahida YR, Wu KC, Jewell DP. Respiratory burst activity of intestinal macrophages in normal and inflammatory bowel disease. *Gut* 1989; 30: 1362-1370 [PMID: 2511088]

Rugveit J, Haraldsen G, Høgåsen AK, Bakka A, Brandtzäg P, Scott H. Respiratory burst of intestinal macrophages in inflammatory bowel disease. *Gastroenterology* 2013; 145: 1481-1484 [PMID: 24409494]

Platt AM, Bain CC, Bordon Y, Sester DP, Mowat AM. An independent subset of TLR expressing CCR2-dependent macrophages promotes colonic inflammation. *J Immunol* 2010; 184: 6843-6854 [PMID: 20483766 DOI: 10.4049/jimmunol.0903987]

Kang GD, Kim DH. Ponciretin and its metabolite ponciretin in bone structure and function. *Int Immunol* 2013; 25: 279-287 [PMID: 23696949 DOI: 10.1046/j.1365-2141.2013.03332]

Lee IA, Park YJ, Joh EH, Kim DH. Soyasaponin AB ameliorates colitis by inhibiting the binding of lipopolysaccharide (LPS) to Toll-like receptor (TLR)4 on macrophages. *J Agric Food Chem* 2011; 59: 13165-13172 [PMID: 22060784 DOI: 10.1021/jf2033818]

Qian Z, Wu Z, Huang L, Qiu H, Wang L, Li L, Yao L, Kang K, Qiu J, Wu Y, Luo J, Liu JJ, Yang X, Yang W, Gou D. Mulberry fruit prevents LPS-induced NF-κB/p65/PAK3 signaling in macrophages and suppresses acute colitis and colorectal tumorgenesis in mice. *Sci Rep* 2015; 5: 17348 [PMID: 26615818 DOI: 10.1038/srep17348]

Regan T, Nally K, Carmody R, Houston A, Shanahan F, Machesky J, Brint E. Identification of TLR10 as a key mediator of the inflammatory response to Listeria monocytogenes in intestinal epithelial cells and macrophages. *J Immunol* 2013; 191: 6084-6092 [PMID: 24198280 DOI: 10.4049/jimmunol.1203249]

Wehner S, Bachholz MM, Schuchtrup S, Rocke A, Schaeffer N, Lysson M, Wirser A, Kalf IJ. Mechanical strain and TLR4 synergistically induce cell-specific inflammatory gene expression in intestinal smooth muscle cells and peritoneal macrophages. *Am J Physiol Gastrointest Liver Physiol* 2010; 299: G1187-G1197 [PMID: 20829523 DOI: 10.1152/ajpgi.00452.2009]

Little MC, Hurst RJ, Else KJ. Dynamic changes in macrophage activation and proliferation during the development and resolution of intestinal inflammation. *J Immunol* 2014; 193: 4684-4695 [PMID: 25261482 DOI: 10.4049/jimmunol.1400502]

Soo SU, Kuffa P, Kitamoto S, Nagao-Kitamoto H, Rousseau J, Kim YG, Núñez G, Kamada N. Macrophages arising from CCR2(+)-monocytic progenitor cells induce anti-inflammatory cell lineages. *Nat Commun* 2015; 6: 8010 [PMID: 26269452 DOI: 10.1038/ncomms9010]

Smith P, Mangan NE, Walsh CM, Fallon RE, McKenzie AN, van Rooijen N, Fallon PG. Infection with a helminth parasite prevents experimental colitis via a macrophage-mediated mechanism. *J Immunol* 2007; 178: 4557-4566 [PMID: 17372014]

Hayashi A, Sato T, Kamada N, Mikami Y, Matsuoka K, Hisamatsu T, Hibi T, Roers A, Yagitá H, Otuki T, Yoshimura A, Kanai T. A single strain of Clostridium butyricum induces intestinal IL-10-producing macrophages to suppress acute experimental colitis in mice. *Cell Host Microbe* 2013; 13: 711-722 [PMID: 23768495 DOI: 10.1016/j.chom.2013.05.015]

Jamontt J, Petit S, Clark N, Parkinson SJ, Smith P. Nucleotide-binding oligomerization domain 2 signaling promotes hyperresponsive macrophages and colitis in IL-10-deficient mice. *J Immunol* 2013; 190: 2948-2955 [PMID: 23396949 DOI: 10.4049/jimmunol.1201332]

Leung G, Wang A, Fernando M, Phan VC, McKay DM. Bone marrow-derived alternatively activated macrophages reduce colitis without promoting fibrosis: participation of IL-10. *Am J Physiol Gastrointest Liver Physiol* 2013; 304: G781-G792 [PMID: 23494123 DOI: 10.1152/ajpgi.00555.2013]

Krause P, Morris V, Greenbaum JA, Park Y, Bjoerheden U, Däbritz J, Brockhausen A, Wirth T, Brückner M, Solinger A, Kupper TS, Krause P, van der Meer R, van der Meer R, van der Meer R. Bone marrow-derived alternatively activated macrophages reduce colitis without promoting fibrosis: participation of IL-10. *Am J Physiol Gastrointest Liver Physiol* 2013; 304: G781-G792 [PMID: 23494123 DOI: 10.1152/ajpgi.00555.2013]

Sun W, Nam, Yi L, Delgado M, Ganea D. Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages. *J Neuroimmunol* 2000; 107: 88-99 [PMID: 10808055]

Kamakana K, Kim WT, Shin YW, Sutterwala FS, Lara-Tejero M, Galán JE, Harhaj E, Flavell RA. Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse. *Immunity* 2006; 25: 941-952 [PMID: 17137799 DOI: 10.1016/j.immuni.2006.09.013]

Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. *J Immunol* 1999; 162: 1707-1716 [PMID: 9973433]

Weinlage T, Dähritz J, Brockhausen A, Wirth T, Brückner M, Belz M, Foell D, Varga G. Granulocyte Macrophage Colony-Stimulating Factor-Activated CD39+CD73+ Murine Monocytes Modulate Intestinal Inflammation via Induction of Regulatory T Cells. *Cell Mol Gastroenterol Hepatol* 2015; 4: 433-449.e1 [PMID: 28210690 DOI: 10.1016/j.cgmh.2015.04.005]

Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. *Ann Rev Immunol* 2009; 27: 313-338 [PMID: 19302043 DOI: 10.1146/annurev.immunol.021908.132657]
Macrophages and gastrointestinal disorders

116 Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, Sato T, Sakuraba A, Kitazume MT, Sugita A, Koganei K, Akagawa KS, Hibi T. Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 2008; 118: 2269-2280 [PMID: 18497880 DOI: 10.1172/JCI34610]

117 Arnold IC, Mathisen S, Schulthess J, Danne C, Hegazy AN, Powrie F. CD11c(+) monocyte/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL-23. Mucosal Immunol 2016; 9: 356-363 [PMID: 26242598 DOI: 10.1038/mi.2015.65]

118 Simon JM, Davis JP, Lee SE, Schaner MB, Gipson GR, Weiser M, Sartor RB, Herfarth HH, Rahbar R, Sadiq TS, Kordja MD, McGovern DP, Lieb JD, Mohile KL, Furey TS, Sheikh SZ. Alterations to chromatin in intestinal macrophages link IL-10 deficiency to inappropriate inflammatory responses. Eur J Immunol 2016; 46: 1912-1925 [PMID: 27159132 DOI: 10.1002/eji.201546237]

119 Boudakov I, Liu J, Fan N, Gulay P, Wong K, Goreczynski RM. Lacking CD200R1 show absence of suppression of lipopolysaccharide-induced tumor necrosis factor-alpha and mixed leukocyte culture responses by CD200. Transplantation 2007; 84: 251-257 [PMID: 17667818 DOI: 10.1097/01.tp.0000269795.04592.cc]

120 Sanelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L, Gwyer E, Sedgwick JD, Barclay AN, Hussell T. A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 2008; 9: 1074-1083 [PMID: 18680812 DOI: 10.1038/nature07167]

121 Cipriani G, Gibbons SJ, Kashyap PC, Farrugia G. Intrinsic Gut Immunity Cell Homeostasis in Crohn's Disease. J Immunol 2016; 196: 7802 [PMID: 26193821 DOI: 10.1038/nncomms8802]

122 Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010; 327: 656-661 [PMID: 20133564 DOI: 10.1126/science.1178331]

123 Haribhai D, Ziegelbauer J, Jia S, Uphichy K, Yan K, Schmitt EG, Harashima A, Harada S, Yamamoto H, Ohta T. Tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2016; 16: 435-445 [PMID: 25753580 DOI: 10.1186/s12885-015-1731-7]

124 Mantovani A, Allavena P. The interaction of anticancer therapies with tumor-associated macrophages. J Exp Med 2015; 212: 345-445 [PMID: 25753580 DOI: 10.1084/jem.20150295]

125 Ma J, Liu L, Che G, Yu N, Dai F, You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010; 10: 112 [PMID: 20338029 DOI: 10.1186/1471-2407-10-112]

126 Zhou Q, Xian M, Xiang S, Xiang D, Shao X, Wang J, Cao J, Yang X, Yang B, Ying M, He Q. All-Trans Retinoic Acid Prevents Melanoma Growth by Stimulating Mesenchymal Stromal Cell-Induced Angiogenesis and M2 Polarization of Tumor-Associated Macrophages. Cancer Immunol Res 2017; 5: 547-559 [PMID: 28515123 DOI: 10.1158/2326-6066.CIR-16-0259]

127 Yamaguchi T, Fushida S, Yamamoto Y, Tsukada T, Kinoshita J, Oyama K, Miyashita T, Tajima H, Ninomiya I, Muneseu S, Harashima A, Harada S, Yamamoto H, Ohta T. Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. Gastric Cancer 2016; 19: 1052-1065 [PMID: 26621525 DOI: 10.1007/s10120-015-0579-8]

128 Li, Uchiyama A, Uehara A, Pereira B, Oguno S, Yokoyama Y, Takeuchi Y, Udey MC, Ishikawa O, Motoji S. MFG-E8 Drives Melanoma Growth by Stimulating Mesenchymal Stromal Cell-Induced Angiogenesis and M2 Polarization of Tumor-Associated Macrophages. Cancer Res 2016; 76: 4283-4292 [PMID: 27197197 DOI: 10.1158/0008-5472.CAN-15-2812]

129 Nakata K, Inagawa H, Nishizawa T, Honda T, Kohchi C, Tomonoto Y, Yoshimura H, Nagase N, Natori S, Terada H, Soma G. Inherent potential for production of tumor necrosis factor-alpha by human intestinal macrophages. Int J Colorectal Dis 2006; 21: 339-347 [PMID: 16091914 DOI: 10.1007/s00384-005-0021-5]

130 Khalil M, Babae A, Lakra R, Försch S, Reeh PW, Wirtz S, Becker C, Neurath MF, Engel MA. Transient receptor potential melastatin 8 ion channel in macrophages modulates colitis through a balance-shift in TNF-alpha and interleukin-10 production. Mucosal Immunol 2016; 9: 1500-1513 [PMID: 26892596 DOI: 10.1038/mi.2016.16]
Wahl LM, Kleinman HK. Tumor-associated macrophages as targets for cancer therapy. *J Natl Cancer Inst* 1998; 90: 1583-1584 [PMID: 9811301]

Andón FT, Digigilo E, Maeda A, Erreni M, Mantovani A, Alonso MJ, Allavena P. Targeting tumor associated macrophages: The new challenge for nanomedicine. *Semin Immunol* 2017; 34: 103-113 [PMID: 28941641 DOI: 10.1016/j.smim.2017.09.004]

Kawahara A, Hattori S, Akiba J, Nakashima K, Taira T, Watari K, Hosoi F, Uba M, Basaki Y, Koufuji K, Shirouzu K, Akiyama S, Kuwano M, Kage M, Ono M. Infiltration of thymidine phosphorylase-positive macrophages is closely associated with tumor angiogenesis and survival in intestinal type gastric cancer. *Oncol Rep* 2010; 24: 405-415 [PMID: 20596627]

Kratochvill F, Neale G, Haverkamp JM, Van de Velde LA, Smith AM, Kawauchi D, McEvoy J, Roussel MF, Dyer MA, Qualls JE, Murray PJ. TNF Counterbalances the Emergence of M2 Tumor Macrophages. *Cell Rep* 2015; 12: 1902-1914 [PMID: 26365184 DOI: 10.1016/j.celrep.2015.08.033]

McClellan JL, Davis JM, Steiner JL, Enos RT, Jung SH, Carson JA, Pena MM, Carnevale KA, Berger FG, Murphy EA. Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1. *Am J Physiol Gastrointest Liver Physiol* 2012; 303: G1087-G1095 [PMID: 23019193 DOI: 10.1152/ajpgi.00252.2012]

Liu YH et al. Macrophages and gastrointestinal disorders

P- Reviewer: Caboclo JL, Contini S, Grizzi F  S- Editor: Gong ZM  L- Editor: Filipodia  E- Editor: Huang Y
